Magenta Therapeutics (MGTA) receives clinical hold letter from FDA related to IND to initiate Phase 1/2 clinical trial of MGTA-117 in patients with AML and MDS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. SPCX
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to Magenta Therapeutics (MGTA) receives clinical hold letter from FDA related to IND to initiate Phase 1/2 clinical trial of MGTA-117 in patients with AML and MDS
(NASDAQ: MGTA) Delayed: 0.70 --0 (-0%)
Previous Close $0.70    52 Week High $ 
Open $1.45    52 Week Low $ 
Day High $0.70    P/E N/A 
Day Low $0.70    EPS $ 
Volume 222,927